Company Description
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific.
The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell.
The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis.
It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014.
10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Country | United States |
Founded | 2012 |
IPO Date | Sep 12, 2019 |
Industry | Health Information Services |
Sector | Healthcare |
Employees | 1,259 |
CEO | Dr. Serge Saxonov Ph.D. |
Contact Details
Address: 6230 Stoneridge Mall Road Pleasanton, California 94588 United States | |
Phone | (925) 401-7300 |
Website | 10xgenomics.com |
Stock Details
Ticker Symbol | TXG |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $39.00 |
CIK Code | 0001770787 |
CUSIP Number | 88025U109 |
ISIN Number | US88025U1097 |
Employer ID | 45-5614458 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Dr. Serge Saxonov Ph.D. | Co-Founder, Chief Executive Officer and Director |
Dr. Benjamin J. Hindson Ph.D. | Co-Founder, President, Chief Scientific Officer and Director |
Justin J. McAnear | Chief Financial Officer |
Eric S. Whitaker Esq. | Chief Legal Officer |
Michael Schnall-Levin | Founding Scientist and Chief Technology Officer |
Cassie Corneau | Manager of Investor Relations and Strategic Finance |
Rebecca Port | Chief People Officer |
James Bryant | Director of Legal |
Nikhil Rao | Director of Product Management |
Florian Baumgartner | Senior Product Manager |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 20, 2024 | 8-K | Current Report |
Jun 13, 2024 | 8-K | Current Report |
Jun 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jun 6, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
May 22, 2024 | 144 | Filing |
May 22, 2024 | 144 | Filing |
May 22, 2024 | 144 | Filing |
Apr 30, 2024 | 10-Q | Quarterly Report |
Apr 30, 2024 | 8-K | Current Report |
Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |